--- title: "A 'happy switch' in the skull: Ruijin Hospital's brain-computer interface for treatment-resistant depression" date: 2026-10-25 category: Brain–Computer Interface site: NeuroAI canonical: https://neuroai.site/a/na-brain-ruijin-depression-bci language: en --- # A 'happy switch' in the skull: Ruijin Hospital's brain-computer interface for treatment-resistant depression > Shanghai Ruijin Hospital has treated 23 treatment-resistant depression patients with a BCI-guided deep brain stimulation system, averaging over 60% symptom relief. A young man who had fought depression for more than fifteen years describes the moment his implant was switched on: he cried without knowing why, as if a weight he had carried since adolescence had simply lifted. He is not cured, and he is not pretending to be. But for the first time in years he got out of bed with energy and went back to work. His "switch" is not a metaphor. It is a deep brain stimulation (DBS) system, tuned by brain-computer interface (脑机接口) neuroregulation, placed inside his skull and chest at Shanghai Ruijin Hospital (瑞金医院). ## Key takeaways - Ruijin Hospital (瑞金医院), affiliated with Shanghai Jiao Tong University, runs a brain-computer interface neuroregulation program for treatment-resistant depression led by Dr. Sun Bomin (孙伯民), director of its functional neurosurgery and BCI neuromodulation center. - The center was founded and the clinical study launched in December 2020, in collaboration with the Shanghai Mental Health Center, the Chinese Academy of Sciences Institute of Neuroscience, the University of Cambridge and a neuroregulation device company. - As of public reporting, 23 patients had been enrolled, with average depression-symptom improvement exceeding 60% after surgery. - One patient, "Wu Xiaotian" (吴晓天), was the tenth enrolled and received surgery in January 2022; he uses a phone app to switch between a daytime "anti-depression" mode and a nighttime "rest" mode that stimulate different targets. - The approach is invasive: electrode chips are implanted in the head and chest to connect directly to emotion-regulating neural circuits and deliver electrical stimulation, with the BCI layer recording neural signals to guide parameter tuning. ## What "treatment-resistant" really means Roughly one in five depressed people does not respond to standard care — drugs, therapy, even electroconvulsive treatment. For them, the illness is not a passing low but a fixed wiring fault. Global estimates put more than 350 million people under depression's weight, and the treatment-resistant slice is a large, underserved group. Ruijin's hypothesis is that certain emotion circuits are stuck in the wrong state, and that precise, adjustable electricity can reset them. The BCI element is what makes it adaptive: the implanted chips record the patient's own neural signals, and those signals — waveforms and biomarkers — tell clinicians how the circuit is behaving, so stimulation parameters can be adjusted rather than left at a fixed setting. ## A switch the patient controls The individual case that has been reported in state media is instructive. The patient received two programmable modes. In the daytime "work" mode he feels alert and engaged; at night a "rest" mode quiets him for sleep. He was given app control because clinicians judged him self-aware enough to manage it — most patients do not adjust their own settings. This is where the "brain-computer interface" label is fair rather than marketing. The loop is brain activity in, signal decoded, stimulation out, response measured — a closed control system, not a simple pacemaker that fires on a timer. ## How far this has actually gone The honest headline number is 23 patients and over 60% average improvement. That is meaningful for a condition with few good options, but it is a small, single-center, open study — not a randomized controlled trial with a placebo arm. We did not find a published large-scale efficacy paper in the materials we reviewed, and "average improvement" masks a wide range of individual outcomes. The system is invasive and irreversible in the sense that hardware is implanted; it is not a first-line option and should not be framed as one. According to Li An, chief scientist at BrainNet (脑机网), closed-loop DBS for mood is one of the more plausible near-term BCI wins in China precisely because it treats a clearly defined, severe, treatment-resistant population rather than promising generalized "mind reading." ## Honest limitations This article does not claim a cure. The 23-patient figure and >60% improvement come from hospital and state-media reports, not an independent peer-reviewed trial we could verify. Long-term effects — years after implantation — are unknown, and the risk of invasive brain surgery (infection, hardware, mood side effects from stimulation) is real. We did not confirm which exact brain targets were used beyond "emotion-regulating circuits," nor any pricing, waiting list or expansion plan. Anyone reading this as a treatment they can book should understand it remains a research procedure inside a registered clinical study. ## What readers can do now - If you or a family member has treatment-resistant depression, ask a psychiatrist about recognized options (medication optimization, ECT, and, in some centers, DBS trials) before assuming any single hospital's program is accessible. - Treat "BCI depression treatment" claims critically: verify the procedure is within a registered clinical trial with ethics approval, not an off-label implementation. - Follow this field by the evidence trail — peer-reviewed outcome papers and regulator engagement — rather than by individual patient stories, which are powerful but not proof. --- Published by NeuroAI (https://neuroai.site/) — https://neuroai.site/a/na-brain-ruijin-depression-bci Free to quote with attribution and a link to the original.